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P2X7 is an ATP-gated membrane ion channel that is expressed by multiple cell types. Brief exposure to ATP 
induces the opening of a non-selective cation channel; while repeated or prolonged exposure induces formation of a 
transmembrane pore. This process may be partially regulated by alternative splicing of full-length P2RX7A pre-
mRNA, producing isoforms that delete or retain functional domains. Here we report cloning and expression of a 
novel P2RX7 splice variant, P2RX7L, that is characterized by skipping of exons 7 and 8. In HEK 293 cells, 
expression of P2RX7L produces a protein isoform, P2X7L, that forms a heteromer with P2X7A. A haplotype 
defined by 6 single nucleotide polymorphisms (rs208307, rs208306, rs36144485, rs208308, rs208309 and 
rs375655596) promotes allele-specific alternative splicing, increasing mRNA levels of P2RX7L and another 
isoform, P2RX7E, which in addition has a truncated C-terminus. Skipping of exons 7 and 8 is predicted to delete 
critical amino acids in the ATP-binding site. P2X7L-transfected HEK 293 cells have phagocytic but not channel or 
pore function, and double-transfected P2X7L and P2X7A cells have reduced pore function. Heteromeric receptor 
complexes of P2X7A and P2X7L are predicted to have reduced numbers of ATP-binding sites, which potentially 
alters receptor function compared to homomeric P2X7A complexes. 






The P2X family contains seven ATP-gated surface membrane receptors (P2X1–P2X7) that form functionally distinct 
homomeric and/or heteromeric ion channels (1). The P2X7 receptor is expressed on cells throughout the human body, 
including the immune and neurological systems, and is implicated in a wide range of physiological processes (2). P2X7 
activation by ATP is a physiological stimulus for the release of interleukin-1β, and proteolytic cleavage of soluble IL-6 
receptor, matrix metalloproteinase-9, CD62L, and CD23 (3-5). Brief exposure to extracellular ATP, released from cellular 
sources in response to cell stress and tissue damage, induces opening of a non-selective cation channel; while repeated or 
prolonged application of ATP results in the formation of a transmembrane pore (6), and ultimately results in cell apoptosis 
via caspase activation (7). In addition, P2X7 functions as a macrophage scavenger receptor, however in contrast to 
channel and pore functions, phagocytic function is inhibited by ATP (8, 9). 
The mechanism by which P2X7 transitions from ion channel to pore in response to the same ligand has not been fully 
elucidated. However, in vitro studies using wild-type and non-dilating mutant rat P2X7 support partial to full occupancy 
of ATP-binding sites as a determinant of transition from desensitized states to sensitized/dilated states respectively (10). 
Furthermore, concentration-dependent saturation of ATP-binding sites may explain opposing P2X7-dependent functions 
observed in human T cell subsets (11). 
ATP binding sites are located between each of the three P2X7 protein subunits that form the cation-selective channel 
(12). For each of the subunits, the location of conserved amino acid residues required for ATP binding can be inferred 
from the agonist-bound crystal structure of zP2X4 (13). Within the first subunit, the ammonium groups of lysine 64 and 
lysine 66, encoded by exon 2 of the P2X7 gene, P2RX7, are predicted to form hydrogen bonds with ATP phosphate 
groups. In the second subunit, ATP interacts with asparagine 292 and arginine 294, encoded by exon 8, and lysine 311, 
encoded by exon 9 (14, 15). P2X7 function can be significantly affected by inheritance of an exon 9 single nucleotide 
polymorphism (SNP) rs28360457 (Arg307Gln) that abolishes P2X7-dependent channel and pore function in human B 
lymphocytes and peripheral blood mononuclear cells (PBMCs) (16). 
Alternative splicing of genes produces a variety of alternatively spliced messenger RNAs (mRNAs) that encode 
distinct proteins (17), and to date, 11 alternatively spliced isoforms of P2RX7 have been identified (18-21). However, only 
2 of these, P2RX7B and P2RX7E, are predicted to be translated to proteins containing the topological features that define 
members of the P2X receptor family, consisting of two transmembrane domains, an extracellular loop and intracellular 
amino and carboxy termini (22). P2RX7B gives rise to a protein with a truncated intracellular C-terminus that retains the 
ATP-binding sites in the extracellular domain, and potentiates channel and pore function when co-expressed with full-
length P2RX7A (19). P2RX7E is identical to P2RX7B except that exons 7 and 8, which encode part of the ATP-binding 
site in the extracellular domain, are also deleted (18).  
There is considerable inter-individual variation in P2X7 function that results from inheritance of nonsynonymous DNA 
sequence variations (23, 24); however a proportion of this variation may result from alternative splicing. The aim of the 
present study was to study inter-individual differences in P2RX7 alternatively spliced isoform expression, in particular 
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mRNAs that lack exons 7 and 8 (EX7_EX8del mRNA) and within this group identify novel mRNA and protein isoforms 
that alter receptor function. Furthermore, we aimed to determine if the expression of alternatively spliced variants was 
heritable.  
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MATERIALS AND METHODS 
Cell Isolation, RNA and DNA extraction 
The experimental protocol was approved by the Nepean and Blue Mountains Local Health District Human Research 
Ethics Committee (06/58). Peripheral blood samples were collected from 24 subjects after obtaining informed consent. 
PBMCs were isolated from whole blood using density gradient centrifugation over Ficoll-Paque™ (GE Healthcare, 
Chicago, IL, USA). Isolated cells were preserved at -80°C in RNAprotect (Qiagen, Hilden, NW, Germany) until RNA 
extraction was performed using Tri-Reagent (Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer’s 
protocol, using 1-bromo-3-chloropropane as an alternative to chloroform. Reverse transcription was performed at 42°C 
for 30 min using a Tetro cDNA Synthesis kit (Bioline, Taunton, MA, USA) and a 1:1 ratio of oligo dT and random 
hexamers unless stated otherwise. DNA was isolated from whole blood using a Wizard DNA Extraction kit (Promega, 
Madison, WI, USA). Sequencing and SNP genotyping were performed at the Australian Genome Research Facility 
(AGRF, St Lucia, QLD, Australia). 
Reverse transcription PCR 
Reverse transcription PCR (RT-PCR) was performed using a Rotor-Gene 2000 cycler (Corbett Life Science; Qiagen) 
under the following cycling conditions: 95°C for 10 min; then 45 cycles of 95°C for 15 s, 55°C for 15 s, 72°C for 15 s 
followed by a melt curve beginning at 72°C for 45 s and increasing to 95°C in increments of 1°C, holding for 5 s at each 
temperature. Each reaction was performed in a volume of 10 µl containing up to 1 µl cDNA, Sensimix Sybr No Rox 
Mastermix (Bioline) and 750 nM of appropriate forward and reverse primer (Optimal primer concentrations were 
determined in preliminary experiments, data not shown). For qualitative assessment of P2RX7 isoform profiles, single 
reactions were performed as described above using primer sets 1-3 (Table 1). Products were separated by electrophoresis 
on a 2% agarose gel containing Sybrsafe DNA stain (Thermo Fisher Scientific, Waltham, MA, USA) and visualized on a 
GelDoc system (Bio-Rad Laboratories, Hercules, CA, USA). Primer sets 4-9 (Table 1) were used for quantitative RT-
PCR (qRT-PCR) and each reaction was performed in triplicate as described above. Expression of each subgroup 
(amplified by primer sets 5-9, Table 1) was measured relative to total P2RX7 expression (amplified by primer set 4, Table 
1). No-template controls and normalization controls using GAPDH primers were included in each run. 
To determine transfection ratios of plasmid RNAs in double-transfected HEK 293 cells, cDNA synthesis was 
performed using oligo(dT)-priming and RT-PCR was performed using Set 4 and Set 9 which detect mRNA transcribed 
from plasmids P2X7A or P2X7L and P2X7E or P2X7L respectively. P2X7E mRNA derived from the plasmid is 
truncated in intron 10, unlike naturally occurring P2X7E mRNA, and is not detected by Set 4 primers in RNA from 
transfected cells. Fold expression above GAPDH was calculated using the following formula: Fold expression = 1/[2 Ct(Set 
4 or 9) - Ct(GAPDH)]. 
Cloning 
PolyA tailed mRNA was reverse transcribed using a Tetro cDNA synthesis kit (Bioline) as described by the 
manufacturer at 42°C for 60 min. P2RX7 specific sequences were amplified from cDNA using previously described 
primers (21) and Phusion Hotstart II High Fidelity polymerase (Finnzymes; Thermo Fisher Scientific) with the following 
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cycling parameters: 98°C for 30 s followed by 34 cycles at 98°C for 10 s, 72°C for 60 s, then 72°C for 5 min, followed by 
cloning into a pGemTeasy vector (Promega) according to the manufacturer’s instructions except that heat shock was 
performed in a heat block rather than a water bath. Colony screening was performed using qRT-PCR to identify specific 
isoform clones as previously described using primer sets 4-9 (Table 1) (25). 
For subcloning into the pcDNA3.1 expression vector, a HindIII site was added to the 5’ end and a GluGlu (EE) Tag 
and XbaI site were added to the 3’end of P2RX7E and P2RX7L fragments using a common forward primer: 5’-
gggaagctttcaccatgccggcctgctgc-3’; and for P2RX7E reverse primer: 5’-
ccctctagactcgagctattccattggcatgtattcgtttaaaccgtcacttccttctccaaaccatttt-3’and for P2RX7L reverse primer: 5’-
ccctctagactcgagctattccattggcatgtattcgtttaaaccgtaaggactcttgaagccactgta-3’ (restriction sites in bold; EE tag sequence 
underlined and P2RX7 specific sequence italicised) by amplification using Phusion HotStart II as described above. After 
double digestion with HindIII and Xba1 (NEB, Ipswich, MA, USA) and gel purification using an Illustra GFX PCR and 
Gelband Purification Kit (GE Healthcare), amplified fragments were ligated into pcDNA3.1 using T4 ligase and 
transformed into JM109 cells (Promega) according to the manufacturer’s instructions. Plasmids were purified from clones 
of interest using a MiniPrep Plasmid extraction kit (Promega) and sequenced to confirm cloning of the correct P2RX7 
isoform sequence. 
Cell lines 
HEK 293 cells were maintained in DMEM: F12 medium containing 10% fetal calf serum, 2 mM L-glutamine, 100 
U/ml penicillin, and 100 g/ml streptomycin (all from Invitrogen, Carlsbad, CA, USA) at 37ºC with 5% CO2 in a 
humidified incubator. PJB3 and P2RX7A-His are cell lines derived from HEK 293, stably transfected with P2RX7A c-
terminal labelled with a Glu-Glu (EE) or His tag, respectively. 
Plasmid DNA (1 g, unless stated otherwise) was transiently transfected into HEK 293 cells (35 mm petri dish of near 
confluent cells) using Lipofectamine 2000 (3 µl/200 µl of Optimem, Invitrogen). Transfected cells were harvested after 
24-48 hr or subjected to Geneticin selection (400 µg/ml) (Gibco; Thermo Fisher Scientific) to generate stably transfected 
cell lines. 
Exon trapping 
DNA sequences spanning P2RX7 exon 7 and flanking intronic sequences were amplified from 2 subjects (one wild-
type and one homozygous minor allele at rs208307) with the addition of BamH1 and Not 1 restriction sites using the 
following primers: left 5’-acgtaaggatcctgggatttgacgaggtatgg-3’ and right 5’- acgtaagcggccgcccatatgccattggtcacac -3’, and 
recombinant Pfu DNA polymerase (Thermo Fisher Scientific) according to the manufacturer’s standard protocol. The 
amplified fragments were ligated into linearized pSPL3 vectors (a kind donation from Dr Robert Formosa, DNA 
Laboratory, Faculty of Health Sciences, University of Malta, Malta) with T4 ligase and transformed into HB101 
competent cells (Promega) as described by the manufacturer. Purified plasmids were transfected into HEK 293 cells and 
harvested for RNA extraction as described above. cDNA synthesis was performed as described above using only oligo dT 
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priming and then PCR was performed as previously described (26) using an annealing temperature of 58°C and pSPL3 
specific primers (SD6: 5'-tctgagtcacctggacaacc-3'; SA2: 5'-atctcagtggtatttgtgagc-3').  
In vitro electrophysiology measurements 
HEK 293 cells were transiently transfected with empty vector, P2RX7A, P2RX7E or P2RX7L constructs. Post-
transfection (48 hr), cells were detached using 0.5 mL Accutase Cell Detachment Solution (Innovative Cell Technologies 
Inc., San Diego, CA, USA) and resuspended at a density of 1 x 106 − 5 x 107 cells/mL in 50% serum-free media and 50% 
external recording solution v/v. The external recording solution comprised 145 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM 
CaCl2, 13 mM D-glucose, and 10 mM HEPES (pH 7.4 with NaOH; ~298 mOsm). The internal recording solution comprised 
85 mM NaCl, 60 mM NaF, 10 mM EGTA, and 10 mM HEPES (pH 7.2 with NaOH; ~285 mOsm). Solutions were filtered 
using a 0.2 m membrane filter (Minisart; Sartorius Stedim Biotech, Goettingen, Germany). Cells were kept in suspension 
by gentle automatic pipetting. Currents generated by P2X7 were recorded using a NPC-16 Patchliner® (Nanion 
Technologies GmbH, Munich, Germany) patch-clamp instrument in the whole-cell configuration. Medium single-hole 
planar NPC-16 chips with an average resistance of ~2.5 MΩ were used. Pipette and whole-cell capacitance were fully 
compensated. Recordings were acquired at 1 kHz with the low pass filter set to 0.33 kHz in PATCHMASTER (HEKA 
Instruments Inc., NY, USA) and performed at room temperature. P2X7 receptor-dependent currents were induced by 
application of 1 mM ATP. The cells were held at -50 mV. Offline analysis was performed using MATLAB R2015a (The 
Math Works Inc., Natick, Massachusetts, United States) and GraphPad Prism 6 (Molecular Devices). Data are shown as 
means ± standard error of the mean (SEM). Statistical analysis was performed using Student's t-test. Statistical differences 
were considered significant when p < 0.05. 
Calcium flux measurements 
Transfected HEK 293 cells (~2 x 106/mL) were washed once and loaded with 2 M Fura-Red acetoxymethyl ester by 
incubation at 37C for 30 min in Ca2+ free HEPES buffered NaCl medium. Cells were washed once and incubated in 
HEPES buffered NaCl with 1 mM Ca2+ for another 30 min. HEK 293 cells were then washed twice and resuspended in 3 
mL HEPES buffered KCl medium at a concentration of 2 x 106/mL. Samples were stirred at 37C and stimulated with 1 
mM ATP after addition of 3.0 mM CaCl2. Cells were analysed by a Becton Dickinson FACSCalibur flow cytometer at 
acquisition rates of ~2000 events/s. The kinetic linear mean channel of fluorescence intensity (1024 channels resolution) 
for each gated subpopulation over successive 2 s intervals was plotted against time and saved into a text file as described 
previously (27).  
Phagocytosis measurements 
Transfected HEK 293 cells (~2 x 106/mL) were resuspended in HEPES-buffered NaCl medium (145 mM NaCl, 5 mM 
KCl, 10 mM HEPES, pH 7.5, plus 5 mM D-glucose, 0.1% BSA, and 0.1 mM CaCl2). For phagocytosis assay, 1.0 µm (5 
µL) carboxylated yellow-green (YG) beads (Polyscience, USA) were added at zero time. The linear mean channel of 
fluorescence intensity for gated HEK 293 cells over successive 10 s intervals was analysed by WinMDI software and 




Ethidium bromide uptake measurements. 
P2X7 pore function in transfected HEK 293 cells was assessed by ATP stimulated ethidium+ uptake as previously 
described using either a plate reader based assay (29) or by time resolved flow cytometry (30). Briefly, cells were bathed 
in a low divalent medium containing ethidium bromide (25 µM) and opening of the P2X7 pore was stimulated by the 
addition of 1 mM ATP allowing passage of ethidium+ into the cell. The increase in fluorescence signal as the ethidium+ 
binds to DNA was monitored over time. 
Preparation of whole-cell lysates 
Cells were placed on ice and washed 3 times with cold phosphate buffered saline (PBS) and harvested by scraping in 
the presence of 0.5 ml PBS with mini-Complete Protease Inhibitor cocktail EDTA-free (PI, Roche Holding AG, Basel, 
Switzerland). Pelleted cells were lysed with 50 µl TX-100 lysis buffer (20 mM Tris pH7.4, 100 mM NaCl, 1% Triton-X-
100) plus PI. After 30 min on ice, whole-cell lysates were harvested by centrifugation (14,000 x g, 10 min at 4°C).  
Western blotting 
Equal amounts of protein were heated at 70°C for 10 min in NuPAGE® loading buffer (Invitrogen) +/- 5mM 
Dithiothreitol (DTT). Samples and markers (Hyperpage, or Novex Sharp Protein Standard, Invitrogen) were separated 
on NuPAGE® Novex 4-12% Bis-Tris mini gel in a XCell SureLock mini-Cell system with NuPAGE® MOPS SDS 
Running Buffer (all from Invitrogen) by running at 60 V for 30 min followed by 120 V for 120 min or Tris-Acetate mini 
gels with NuPAGE® Tris-Acetate SDS Running Buffer as indicated. Proteins were transferred to a PVDF membrane 
(Thermo Fisher Scientific) using an XCell II Blot Module (Bio-Rad laboratories, Hercules CA, USA; 350 mA for 50 
min) in NuPAGE® Transfer Buffer (Invitrogen).  
After blocking for 2 hr or overnight with non-animal protein (NAP)-blocker (G-Biosciences, St. Louis, MO, USA) 
and washing 3 times in 0.5% Tween20 in Tris-Buffered Saline (TBS) for 10 min with shaking, the membrane was 
incubated with primary antibodies (polyclonal rabbit anti–Glu-Glu antibody, Bethyl Laboratories, Montgomery, TX, 
USA, 1:10,000) or extracellular P2X7 antibody, APR-008, (anti P2X7, Alomone Labs, Jerusalem, Israel; 1:5,000) for 2 
hours, washed again as above and probed with goat anti-rabbit horseradish peroxidase (Santa Cruz Biotechnology, 
Dallas, TX, USA, 1:10000) for 1 hr. After further washing, bands were visualized using a SuperSignal West Pico or 
Femto kit (Thermo Fisher Scientific) on a Gel Doc System (Bio-Rad). 
For near infrared immunoblotting, proteins were transferred to Immobilon-FL membranes (Merck Millipore, 
Tullagreen, Ireland) by overnight transfer at 30 V. Membranes were rinsed with water and dried for 1 hr before re-
wetting and blocking for 1 hr in Odyssey Blocking Buffer (OBB, Licor, Lincoln, NB, USA) prepared in TBS as 
described by the manufacturer. Primary antibodies were used as described above; except they were prepared in OBB 
plus 0.1% Tween 20. Washes were performed as above, but with 0.1% TBS. Blots were incubated with secondary 
antibody (800CW Donkey anti-Rabbit IgG, Licor) diluted 1:20000 in OBB plus 0.1% Tween 20 plus 100 µg/ml sodium 
dodecyl sulfate for 1 hr in the dark. The blots were washed 4 times, rinsed in TBS and air dried in the dark. Images were 
collected on an Odyssey Fc Imager (Licor). 
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Immunofluorescent Staining for Flow cytometry 
Transfected HEK 293 cells were stained either directly with anti-P2X7 monoclonal antibody (mAb) L4-FITC (1:200), 
or indirectly with anti-P2X7 (1:40) and goat anti rabbit IgG-FITC (Santa Cruz Biotechnology,1:200) and analysed using a 
FACSVERSE flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). 
Crosslinking of Cell Surface Receptors 
All crosslinking was performed on cells attached to culture flasks. To crosslink surface receptors with 
Bis[sulfosuccinimidyl]suberate (BS3, Thermo Fisher Scientific), cells were washed 3 times with cold PBS (pH 8) and 
incubated with 1.25 mM BS3 for 30 min at RT. The reaction was quenched by addition of 20 mM Tris HCl (pH 7.5) 
followed by incubation at room temperature for 15 min. Cells were harvested for western blotting as described above. 
Crosslinking with 0.5 mM 3,3'-dithiobis(sulfosuccinimidyl propionate) (DTSSP, Thermo Fisher Scientific) was performed 
as above except that PBS (pH 7.4) was used. 
Proximity Ligation Assay 
Dishes (35 mm) of subconfluent HEK 293 cells stably transfected with EE-labelled P2RX7A or P2RX7L were 
transiently transfected with 0.25 µg of P2RX7A-AcGFP plasmid. After 24 hrs, cells were trypsinized and a 1/5 dilution 
replated onto poly-D-Lysine coated coverslips in a 24 well plate. After a further 24 hrs, cells were fixed by washing once 
with cold PBS, then incubating for 20 min on ice with 4% paraformaldehyde in PBS. Fixed cells on coverslips were 
washed twice with PBS and permeabilised with 0.5% Triton X-100 in PBS for 10 min at RT, then blocked for 30 min at 
RT in 5% FCS in PBS. 
Coverslips were incubated overnight at 4°C with rabbit anti-EE (1/800) and mouse anti-GFP antibody (1/800, Santa 
Cruz Biotechnology). Coverslips were then attached to slides with Twinsil (Picodent, Wipperfürth, NW, Germany), cell-
side-up before proceeding with the proximity ligation assay (PLA) using a Duolink® In Situ Orange mouse/rabbit starter 
kit (Sigma-Aldrich, St Louis, MO, USA) according to the manufacturer’s instructions. Signals were observed with an 
Eclipse 80i fluorescent microscope with a 40x objective using B2A, G2A and UV-2A filter sets (Nikon Instruments, 
Melville, NY, USA) to detect AcGFP, PLA and DAPI signals, respectively. Images were collected with a Qicam 
Fast1394 camera (Qimaging, Surrey, BC, Canada) using a constant, optimised exposure time for collection of all images.  
Nickel affinity chromatography 
Pull-down of His-tagged proteins was performed using EZview™ Red HIS-Select® HC Nickel Affinity beads as 
described by the manufacturer (Sigma- Aldrich). Briefly, whole-cell lysates (~1 µg protein) were incubated with pre-
equilibrated beads in the presence of 10 mM or 12.5 mM Imidazole in PBS plus 1% Tx-100 plus PI, for 2 hr at 4ºC with 
slow rotation, then washed 4 times with the same buffer. Proteins were eluted from the washed pellet in 15 µl of NuPAGE 
loading buffer (Invitrogen) with or without 5 mM DTT as required. 
Statistical analyses 
Fishers’ exact tests were performed using an online tool (www.quantpsy.org/fisher/fisher.html) and one-way ANOVA 
with Tukey’s post hoc analyses were performed in GraphPad Prism v7. Pairwise linkage disequilibrium (LD) was 




Expression patterns of P2RX7 mRNA isoforms vary between human subjects 
PBMCs from 22 human subjects were used to qualitatively determine inter-individual differences in expression of 
P2RX7 mRNA isoforms. PCR primers (Sets 1-3, Table 1A) were designed to span known alternatively spliced regions of 
the P2RX7 primary mRNA transcript. Each set of primers generated amplicons of different sizes, depending on the 
isoforms present in the sample which, when assessed by Southern blot, enabled a qualitative analysis of P2RX7 isoform 
expression. The predicted banding patterns in the presence of all known P2RX7 isoforms are represented schematically in 
Fig. 1A (left panel) alongside 2 examples of typical isoform expression patterns seen in individuals (Fig. 1A, central and 
right panels). Reduced complexity of banding patterns in individuals compared to the predicted patterns indicated that a 
subset of P2RX7 mRNA isoforms are normally expressed and in varying abundances. In subject 1, absence of a 130 base 
pair (bp) band generated by primer set 1 excluded the presence of P2RX7V7, P2RX7ΔE2 and P2RX7V4; absence of 385 
and 35 bp bands from Set 2 excluded the presence of P2RX7D, and absence of a 199 bp band from Set 3 excluded 
P2RX7E. Weak detection of a 438 bp band generated by Set 1 and a 159 bp band generated by Set 2 indicated low levels 
of isoforms P2RX7G and H, and P2X7C and F, respectively. From these data it was inferred that of 12 known P2RX7 
isoforms, subject 1 predominantly expressed isoforms P2RX7A, P2RX7B and P2RX7J as well as small amounts of 
isoforms P2RX7C, F, G and/or H. Of interest was the inter-individual differences in the presence of the 199 bp band 
detected by Set 3 (Fig. 1A, arrow) representing Ex7_Ex8del mRNAs, which was absent in 10 of 22 subjects tested. 
P2RX7 mRNA isoforms can be grouped on the basis of specific exon deletions or insertions (18). A set of 6 primers 
were designed to enable relative quantification of each isoform sub-group as a percentage of total P2RX7 mRNA in 24 
subjects (Table 1B, primer sets 4-9, and Fig. 1B). In PBMCs, the inserted intron 10 (Ins Int 10) mRNA group (containing 
P2RX7B, P2RX7C, P2RX7E, P2RX7G, P2RX7V4 and P2RX7V7) was the most abundant in each individual (mean = 
60.7% ± 12.2 SD), followed by deletion Exon 4 (P2RX7C and P2RX7F; mean = 10.4% ± 4.8 SD), and deletion Exon 8 
(P2RX7J, P2RX7F and P2RX7V4; mean = 5.9% ± 3.0 SD). Ins N3 variants (P2RX7G and P2RX7H) were consistently 
least abundant (Fig. 1B; mean = 0.5% ± 0.7 SD). Levels of Ex7_Ex8del mRNA (P2RX7E) were detected at levels ranging 
from 0-13% of total P2RX7 (mean = 3.2% ± 3.4 SD), consistent with qualitative analyses. 
Isolation of a novel EX7_EX8del mRNA variant 
To investigate whether inter-individual variation in EX7_EX8del mRNA variants was due to P2RX7E levels alone or 
the presence of other variants, P2RX7E mRNA was cloned from 2 subjects that expressed high levels of EX7_EX8del 
mRNA. Colony screening was performed using primer sets 4-9 (Table 1B) to identify clones of specific isoforms as 
previously described (25). In addition to isolating P2XR7E mRNA, 5 novel P2RX7 mRNA variants were identified (Fig. 
S1). Of interest was a novel EX7_EX8del mRNA isoform designated “P2RX7L” (Fig. 2A and S1; GenBank accession, 
MK465687) that was predicted to be translated into a 506 amino acid (aa) protein retaining the long intracellular C-
terminus of P2X7A (Fig. 2B and S2). 
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EX7_EX8del mRNA levels are associated with an intron 6 SNP, rs208307 
From our SNP genotyping database, we identified four P2RX7 SNPs that were predicted to influence exon 7 and 8 skipping: 
rs208307 (acceptor splice site in intron 6), rs503720 (upstream of the intron 7/exon 8 junction), rs7958311 (exon 8 missense 
mutation), and rs7958316 (exon 8 missense mutation at an exonic splice enhancer site). Allele frequencies of these SNPs 
were compared between subjects that expressed EX7_EX8del mRNA (Table 2). The minor allele frequency (MAF) of 
rs7958311 was significantly higher in EX7_EX8del negative subjects (MAF = 0.5) compared to positive subjects (MAF = 
0.15; n = 17; p = 0.02). Conversely the MAF for rs208307 was 0 for EX7_EX8del negative subjects compared to 0.43 for 
EX7_EX8del positive subjects (p = 0.007). No associations were found between EX7_EX8del mRNA levels and the other 
two SNPs (rs503720 and rs7958316). 
Amongst the EX7_EX8del positive subjects, the lowest level of expression was seen in subjects wild-type at rs208307. 
To determine if EX7_EX8del mRNA levels were associated with gene-dosage of rs208307 we analysed EX7_EX8del 
mRNA levels as a percentage of total P2RX7 mRNA in wild-type (CC), homozygote minor allele (GG) and heterozygote 
(CG) subjects and found a difference between the three groups (one-way ANOVA p < 0.0001 followed by Tukey’s post 
hoc analysis). Expression of EX7_EX8del mRNA was highest in subjects homozygous for the minor allele (P2X7L mean 
expression = 9.1% ± 4.5 SD), intermediate in heterozygote (mean = 5.0% ± 1.8 SD) and lowest in wild-type participants 
(mean = 0.5% ± 1 SD, Fig. 3A). Gene dosage of rs7958311 was not associated with levels of EX7_EX8del mRNA (data 
not shown). 
A SNP haplotype block tagged by rs208307 regulates EX7_EX8del mRNA levels 
The rs208307 SNP is located 5 bp from the intron 6/exon 7 boundary, and is predicted to disrupt a branch-point site 
associated with exon splicing [Human Splice Finder 2.4.1 software (HSF), http://www.umd.be/HSF/] (32). An exon-
trapping system was used to study the effect of rs208307 wild-type (CC) and homozygous minor allele (GG) on P2RX7 
splicing (Fig. 3B). A 494 bp DNA fragment encompassing P2RX7 exon 7 and flanking intronic sequences was cloned 
from one wild-type (CC) subject and one homozygous minor allele (GG) subject and inserted into a pSPL3 exon trapping 
vector. HEK 293 cells were transiently transfected with either CC, GG or empty trapping vectors. RT-PCR was performed 
on extracted RNA using plasmid specific primers SD6 and SA2. Cells transfected with plasmid derived from the wild-
type subject, produced a 393 bp band (Fig. 3C), which was confirmed by sequencing to contain P2RX7 exon 7. The 
plasmid derived from the homozygous minor allele subject generated 2 fragments, a 393 bp amplicon containing P2RX7 
exon 7, as well as a 263 bp amplicon confirmed by sequencing to contain only Exon 1 and Exon 2 of pSPL3, consistent 
with partial exon 7 skipping (Fig. 3C).  
Sequencing of the 494 bp fragments inserted into the exon trapping plasmid identified additional SNPs surrounding 
rs208307 that were subsequently analysed in silico for their effect on alternative splicing (HSF and RegRNA software, 
http://regrna2.mbc.nctu.edu.tw/) (32, 33). The rs208307 homozygous minor allele subject was homozygous for minor 
alleles at rs208306, rs36144485 (both in intron 6), and rs208308, rs208309, and rs373655596 (all in intron 7). In silico 
analysis predicted that rs208306 SNP would introduce a new regulatory site that may enhance alternative splicing 
(RegRNA) and an exon identity element analysis predicted disruption of a silencing element (HSF). The rs36144485 
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variation is a 4 bp deletion (TGTT) that is predicted to disrupt silencing motifs IIE (intron identity elements) sites. The 
rs208307 wild-type subject was wild-type at each of these SNPs, however heterozygote at rs17526121 in intron 6 that is 
predicted to disrupt a potential branch-point site (HSF). 
To determine if the 7 variants identified in introns 6 and 7 are inherited as a haplotype block tagged by rs208307, a 
further 8 subjects were genotyped (Table 3) and pairwise linkage disequilibrium (LD) was calculated using PLINK 
(http://pngu.mgh.harvard.edu/purcell/plink/) (31). Complete LD was found between rs36144485, rs208307, rs208308, 
rs208309 and rs373655596 (r2 = 1); and rs208306 was in high LD with each of these 5 SNPs (r2 = 0.8). 
Homomeric P2X7L complexes are expressed on the cell surface membrane 
To study protein expression of EX7_EX8del alternatively spliced mRNAs, P2X7A (PJB3), P2X7E and P2X7L EE-
labelled constructs were transfected into HEK 293 cells. Whole-cell lysates of transfected cells were analysed by Western 
blot and probed using anti-EE. Proteins were detected at ~68, 31 and 58 kDa (Fig. 4A, lanes 2, 3, and 4) which 
corresponded to the expected molecular weights (MW) of P2X7A, P2X7E, and P2X7L, respectively. To study cell surface 
expression of EX7_EX8del alternatively spliced protein isoforms, HEK 293 cells were transiently transfected with 
P2X7A, E or L and analysed by flow cytometry after labelling with extracellular anti-P2X7 polyclonal antibody (pAb) 
APR008 raised against amino acids 136-152 of P2X7A and encoded by exons 4 and 5 (Fig. 4B, top panels). Surface 
expression of P2X7A and P2X7L, but not P2X7E was observed. Lack of surface expression of P2X7E is consistent with 
absence of the C terminal that contains key structural motifs required for cell surface localization (34, 35). P2X7 surface 
expression was also analysed using the L4 mAb that binds to an epitope around Arg307 and inhibits receptor function 
(36). L4 binding was detected on the surface of P2X7A transfected HEK 293 cells, however no binding was detected in 
P2X7E or P2X7L transfected cells (Fig. 4B, bottom panels). 
To determine if P2X7L protein isoforms interact on the surface membrane, HEK 293 cells were transiently transfected 
with EE-tagged P2X7A or P2X7L expression constructs. Proteins on the cell surface were crosslinked by treatment with 
BS3, a membrane impermeable non-cleavable protein crosslinker (Fig. 4C). For BS3-treated P2X7A-transfected cells, 
bands at > 160kDa, ~130 kDa and ~70 kDa, corresponding to trimers, dimers and monomers respectively, were detected 
by Western blotting (Fig. 4C, lane 2). For BS3-treated P2X7L-transfected cells, bands at ~ 110 kDa and ~55 kDa were 
detected (Fig. 4C, lane 4), which corresponded to the expected MWs of dimers and monomers respectively. Although 
dimers of P2X7L crosslinked at the cell surface were identified, P2X7L trimers were not detected (Fig. 4C, lane 4). 
Heteromeric P2X7L and P2X7A complexes are expressed in the cell cytoplasm and surface membrane 
Nickel affinity chromatography was used to determine if P2X7A and P2X7L form heteromeric complexes in the cell 
cytoplasm. HEK 293 cells were stably transfected with P2X7A-His and P2X7L-EE expression constructs or P2X7L-EE 
alone. EZview His-Select beads were used to pull down proteins interacting with P2X7A-His from whole-cell lysates in the 
presence of 10 mM imidazole. Samples of the whole-cell lysates and the bead eluates were separated by SDS-PAGE and 
Western blot was performed using near infrared immunoblotting (Fig. 5A). When expressed together in the same cell line, 
P2X7L-EE co-eluted with P2X7A-His (Fig. 5A, lane 4), but when expressed alone, P2X7L-EE  was only detected at residual 
levels in the bead eluate (Fig 5A, lane 3) indicating that P2X7A and P2X7L interact in a heteromeric complex. 
14 
 
A Duolink proximity ligation assay (PLA) was used to validate the observation that P2X7L interacts with P2X7A. 
Non-transfected HEK 293 cells or cells stably transfected with P2X7L-EE or P2X7A-EE were transiently transfected with 
P2X7A-AcGFP and a PLA was performed. All three cell lines were successfully transfected with P2X7A-AcGFP (green 
fluorescence, Fig. 5B, upper row). Positive PLA signals were detected in both P2X7A-EE and P2X7L-EE stable cell lines 
(red fluorescence, Fig. 5B, middle row), but not in HEK 293 cells, indicating that P2X7L-EE may form a heteromeric 
complex with P2X7A-AcGFP. 
To determine if P2X7A and P2X7L form heterotrimers in the cell surface membrane, HEK 293 cells stably transfected 
with P2X7A-His and P2X7L-EE or P2X7L-EE alone were treated with DTSSP, a membrane impermeable crosslinker. 
Nickel affinity chromatography was used to purify receptor complexes containing P2X7A-His from whole-cell lysates in 
the presence of 12.5 mM imidazole. Bead eluates and whole-cell lysates were separated by non-reducing SDS-PAGE and 
near infrared immunoblotting Western blots were performed. The presence of P2X7L alone or P2X7L and P2X7A in 
whole-cell lysates was confirmed by probing duplicate blots with anti-EE to detect P2X7L-EE (Fig. 6A lanes 1 and 2, 
between 50 and 60 kDa) or with anti-P2X7 antibody (APR008) that detects both P2X7A-His (Fig. 6A lane 4, between 60 
and 80 kDa) and P2X7L-EE (Fig. 6A Lanes 3 and 4 between 50 and 60KDa). Although the absence of DTT has resulted 
in a diffuse banding pattern, faint bands at ~110kDa and ~170kDa corresponding to the predicted MW of P2X7L dimers 
and trimers, respectively, were detected in whole-cell lysates of cells expressing P2X7L alone (Fig. 6A lane 3) and less 
distinctly in the other lanes. As observed previously (Fig. 5), small amounts of P2X7L-EE were eluted from whole-cell 
lysates using the His select beads (Fig. 6A, lanes 1 and 3). Probing blots with anti-EE and anti-P2X7 detected a band at 
~170 kDa corresponding to the predicted MW of a P2X7L-EE homotrimer (Fig. 6B lane, 1 and 3, bold arrows). 
Three distinct bands corresponding to the MWs of P2X7A-His monomers, dimers and trimers were detected in bead 
eluates of doubly transfected cells probed with anti-P2X7 (Fig. 6B, lane 4), but not with anti-EE (Fig. 6B lane 2). A 
Western blot of bead eluates from doubly transfected cells probed with anti-EE (Fig. 6B lane 2, chevron arrow) detected a 
complex that migrated midway between the position of the P2X7A dimer (A2, ~160kD) and trimer (A3,~260kD, Fig. 6B 
lane 4) and slightly behind the P2X7L trimer faintly detectable at ~170kDa (Fig. 6B lanes 1 and 3), consistent with 
formation of a heterotrimer of P2X7A-His and P2X7L-EE. At the corresponding position on the blot probed with anti-
P2X7 (Fig 6B, lane 4) only a dark smear rather than a distinct band was observed. Heterotrimerization and/or cell surface 
crosslinking may have obscured the anti-P2X7 binding site as it is located in the extracellular domain but not the anti-EE 
epitope which is located on the intracellular C terminus of P2X7L-EE. The doublet observed in Fig. 6B. (lanes 1 and 2 at 
approximately 110kDa) is likely to correspond to endogenous HEK293 proteins with naturally occurring EE and His 
epitopes. 
P2X7L has phagocytic but not channel or pore function 
To determine whether EX7_EX8del protein isoforms form functional receptors, patch-clamping and Ca+ flux was used 
to measure channel function, and ethidium+ uptake measured by time resolved flow cytometry was used to analyse pore 
function in HEK 293 cells transiently transfected with either P2X7A, P2X7L or P2X7E. In addition, phagocytic function, 
in the absence of ATP, was analyzed by measuring the uptake of YG beads using flow cytometry (8, 9, 37). Channel and 
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pore function were not detected in either P2X7E or P2X7L transfected cells (Fig. 7A, B and C), however P2X7L showed 
the same level of phagocytic function compared to P2X7A (Fig. 7D). P2X7E, which is not trafficked to the cell surface, 
failed to confer phagocytic function (Fig. 7D). 
P2X7 receptor pore function is altered following double-transfection of P2X7A and P2X7L 
Since co-assembly of P2X7A with the C-terminus deleted P2X7B protein isoform potentiates P2X7 pore function (19), 
ethidium+ uptake was studied in HEK 293 cells that had been double-transfected with P2X7A and either P2X7E or P2X7L. 
P2X7A was co-transfected with equal amounts of P2X7E or P2X7L (1 µg total plasmid DNA) and cells transfected with 
single plasmids were included as controls. Pore function was measured by ATP-induced ethidium+ uptake using a plate 
reader-based assay. Confirming earlier observations using time resolved flow cytometry (Fig 7C), single transfections of 
P2X7L and P2X7E showed no ethidium+ uptake. Pore function was unchanged following co-transfection of P2X7A and 
P2X7E, however, co-transfection of P2X7A and P2X7L reduced the rate of ethidium+ uptake by ~50% (Fig. 8, p < 0.0001). 
Cell surface expression of P2X7A and P2X7E or P2X7L could not be measured by flow cytometry as currently there are 
no antibodies that differentiate P2X7A from EX7_EX8del protein isoforms. Expression of protein isoforms was inferred 
from plasmid-derived mRNA expression in transfected cell populations using primer sets 4 (mRNA derived from P2X7A 
and P2X7L plasmids) and 9 (mRNA from P2X7E and P2X7L plasmids; Table 1). Cells double-transfected with P2X7A 
and P2X7E showed similar levels of mRNA expression determined by sets 4 and 9. Similarly, approximately equal amounts 
of P2X7A and P2X7L mRNAs were expressed, with P2X7A + P2X7L mRNAs measured by set 4 expected to be double 




In this paper, we report cloning and expression of a novel P2RX7 splice variant, P2RX7L, which is characterized by 
skipping of exons 7 and 8. A six SNP haplotype was found to induce partial allele specific alternative splicing, increasing 
mRNA levels of EX7_EX8del splice variants. Deletion of exons 7 and 8 will excise asparagine 292 and arginine 294 
residues, both of which are predicted to interact with ATP in the ligand-binding site of human P2X7 (38). Significantly, 
P2X7L was found to form a heteromeric complex when co-expressed with P2X7A. In transfected HEK 293 cells, P2X7L 
showed phagocytic, but not channel or pore function. Compared to P2X7A alone, double-transfection of P2X7L and 
P2X7A reduced pore function by ~50%. 
P2RX7 mRNA isoforms were studied in human PBMCs using a novel method that combined qualitative RT-PCR and 
qRT-PCR. For qualitative RT-PCR, three primer sets (Table 1, sets 1-3) were designed to distinguish between splice 
isoforms based on amplicon size whereas for qRT-PCR, P2RX7 specific primers were designed to target sites of either 
intron-retention, exon-skipping or alternative exon insertion (Table 1, set 4-9). In contrast to the qualitative primer sets, 
quantitative primer sets were designed to detect a single splicing feature, generate small amplicons to ensure amplification 
efficiency, and where possible span exon-exon boundaries. Considerable inter-individual variation was observed in both 
qualitative and quantitative analyses particularly with respect to Ex7_Ex8del mRNA levels (Fig. 1A and B). This finding 
was significant considering EX7_EX8del is predicted to excise the P2X7 ATP-binding site based on mutagenesis studies 
and the crystal structure of zP2X4 (38, 39). 
Participant genotypes were examined, and an association was found between low or absent EX7_EX8del and the 
minor allele at rs208307 (641-5C > G) that is located at an acceptor splice site in intron 6. In contrast, the highest levels of 
EX7_EX8del mRNAs were found in rs208307 homozygote minor allele subjects (Table 2). EX7_EX8del mRNA 
transcript levels correlated with allele-dosage of rs208307, with the highest levels in homozygote, intermediate in 
heterozygote, and lowest in wildtype (Fig.3A). However, it is likely that other pre-mRNA processing events regulate 
skipping of exons 7 and 8, as rs208307 homozygote minor allele participants continue to express mRNA isoforms that 
retain exons 7 and 8. Furthermore, some subjects homozygote wild-type at rs208307 also expressed EX7_EX8del mRNAs 
at low levels. These results are consistent with partial allele-specific alternative splicing that was confirmed using an exon 
trapping system by cloning DNA fragments encompassing P2RX7 Exon 7 and flanking intronic sequence into an pSPL3 
trapping vector. The haplotype tagged by rs208307 (minor alleles at rs208307, rs208306, rs36144845, rs208308, rs208309 
and rs373655596) demonstrated partial allele specific alternative splicing by generating transcripts both with and without 
inclusion of Exon 7 (Fig. 3C). Similar to other genes (40), we have shown that P2RX7 undergoes allele-specific 
alternative splicing, and that inheritance contributes to differences in relative abundances of EX7_EX8del mRNAs. 
However, multiple factors regulate alternative splicing including cell type-specific and physiological mechanisms (41), for 
example, expression of P2X7B is increased in B lymphocytes following stimulation with phytohemagglutinin (19). 
Alternative splicing has been shown to produce eleven human P2RX7 mRNA isoforms, however only two truncated 
protein isoforms, P2X7B and P2X7J, have previously been studied at the protein level (18-21, 42). P2RX7B retains intron 
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10, which introduces a new stop codon and encodes a truncated protein lacking the last 171 aa and containing an alternate 
18 aa after TM2 (19). P2X7B forms a heterotrimer with P2X7A when exogenously expressed in  Xenopus laevis oocytes 
and increases receptor functions when co-transfected with P2X7A in HEK 293 cells (19). P2X7J lacks the entire 
intracellular C-terminus, TM2, and the distal third of the extracellular loop (20, 42). In HEK 293 cells, P2X7J also forms a 
heterotrimeric complex with P2X7A, however, P2X7 functions are inhibited in co-transfected Madin-Darby canine kidney 
cells (43). In the present study, a novel EX7_EX8del isoform, P2RX7L, was identified after mRNA sequences were 
cloned from subjects that expressed relatively high levels of EX7_EX8del mRNA isoforms. In contrast to a previously 
identified EX7_EX8del isoform, P2RX7E, it was predicted that P2RX7L would retain the long intracellular C-terminus 
including key structural motifs required for cell surface localization (34, 35). In HEK 293 cells, both P2RX7E and 
P2RX7L, were translated into P2X7E and P2X7L protein isoforms, respectively (Fig. 4A), but only P2X7L was expressed 
on the cell surface (Fig. 4B). Lack of surface expression of P2X7E is consistent with previous studies that show the long 
C-terminus is required for membrane trafficking and localisation (34, 44). P2X7B, which has the same alternative C-
terminus as P2X7E, has previously been shown to inefficiently traffic to the cell surface (45). In singly transfected cells 
P2X7L formed homotrimers (Fig. 6A, lane 3), and in double transfected cells co-assembled with P2X7A to form 
heterotrimers (Fig 6B, lane 2). It is of interest that the P2X7 L4 mAb bound to P2X7A and not to P2X7L (Fig. 6B), which 
would be consistent with loss of the L4 epitope around Arg307 resulting from skipping of exons 7 and 8. 
There is considerable inter-individual variation in P2X7 receptor function, including channel gating, ion sensitivity and 
ligand binding (24, 46). This variation has been largely attributed to inheritance of amino acid-altering non-synonymous 
SNPs (2). However, the present study shows that partial allele-specific alternative splicing may potentially affect receptor 
function by altering the proportional of fully functional P2X7A homotrimers expressed at the cell surface through the 
formation of heteromers. Double-expression of P2X7A and P2X7L in a cell model reduced receptor pore function by 
~50%, and a previous study in 200 healthy human subjects found rs208307, labelled as “IVS6 TTTG-17TTTGTTTG” in 
Denlinger et al. (23), and rs36144845 (IVS6 G-5C), were present in those with low pore function who were wild-type at 
the rs3751143 (A1513C) loss-of-function SNP (23). 
The recognition that partial allele-specific alternative splicing produces functional P2X7 protein isoforms that alter 
receptor function adds complexity to the design and interpretation of P2RX7 genetic association studies. Most studies of 
P2RX7 and disease have focused on non-synonymous SNPs that alter protein sequence; however, this present study has 
found intronic SNPs that contribute to variation of protein sequence between individuals and an examination of rs208307 
allele frequencies in previous candidate-gene and disease association studies may be considered in light of the phenotypic 
consequences of allele-specific alternative splicing (40). 
The consequences of allele- and tissue- specific alternative splicing on P2X7 protein isoform expression have 
important practical applications for P2X7 as a pharmacological target. The presence of tissue-specific isoforms may aid 
the design of drugs with specific actions on given P2X7-dependent physiological processes. Furthermore, an 
understanding of alternative splicing is required for emerging RNA therapies that use RNA interference methods to 
silence specific mRNA isoforms. 
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In conclusion, we have identified a component of the genetic regulation of P2RX7E and P2RX7L mRNA levels in 
native human cells and found that the P2X7L protein isoforms alters pore and phagocytic function in a cell model. 
Although a previous study found a potential association between rs208307 and rs36144845 and low pore function in 
human subjects (23), further studies are required to fully characterize the effects of P2X7L on receptor function. At 
present, studies are limited by the absence of antibodies that differentiate EX7_EX8del protein isoforms from P2X7A, 
however advances in proteomic techniques are expected to provide a better understanding of P2X7 receptor structure and 
function resulting from alternative splicing. 
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Figure 1: Qualitative and Quantitative Expression patterns of P2RX7 mRNA isoforms in PBMCs 
Primer sets 1-3, described in Table 1A, were used to qualitatively assess inter-individual differences in P2RX7 
mRNA isoform expression in PBMCs from human subjects (n = 22) by agarose gel electrophoresis of RT-PCR 
products. Left panel: predicted banding patterns; centre and right panel: banding patterns from 2 representative 
subjects. The most commonly observed difference between subjects was the presence or absence of a 199 bp band 
in Subject 2 lane S3 (arrow). Panels are from the same image with irrelevant lanes cropped out. *Molecular size 
marker: 100 bp DNA ladder; **Negative control. B) Quantitative assessment of the abundance of P2RX7 mRNA 
isoform groups relative to total P2RX7 mRNA was made by qRT-PCR using primer sets 4-9 (Table 1B) and 
expressed as a percentage of total P2RX7 mRNA in PBMCs from human subjects (n = 20).  
 
Figure 2: Comparison of novel isoform P2X7L with P2X7A and P2X7E 
Schematic representation of mRNA isoforms of P2RX7A, E and L. Exons are represented by alternating black 
and white rectangles. The horizontal line linking exons 10 and 11 in P2RX7E represents Int 10 (M: position of 
translation start codon; ●: translation stop codon). B) Amino acid length and predicted molecular weights of 
P2X7A, E and L. 
 
Figure 3: EX7_EX8del mRNA levels are associated with gene dosage at rs208307 
Expression levels of EX7_EX8del mRNA between subjects who were wild-type (n = 10), 
heterozygous (n = 8) or homozygous (n = 2) at rs208307. There was a difference between the 3 
groups (one-way ANOVA p < 0.0001 followed by Tukey’s post hoc analysis). * p = 0.0005; ** p < 0.001; 
*** p < 0.018. WT: wild-type; HET: heterozygote; HOM: homozygote. B) Schematic representation of 
the structure of the exon trapping vector, pSPL3, containing a 494 bp fragment of P2RX7 spanning Exon 7 
from 2 subjects either WT or HOM, respectively at rs208307. MCS: multiple cloning site. C) HEK 293 Cells 
were transfected with one of the 2 plasmids or empty pSPL3 vector and total mRNA was isolated. RT-PCR was 
performed, and PCR products were resolved on a 2% agarose gel. The WT plasmid generated a 393bp mRNA 
fragment, while the mutant plasmid generated a 393bp fragment and a 263bp fragment identical to the empty 




Figure 4: Protein expression of P2X7L. 
A) Western blot analysis of whole-cell lysates from HEK 293 cells transfected with EE-labelled P2X7A, E 
and L expression constructs. Whole-cell lysates were immunoblotted with anti-EE antibody. Proteins were 
detected at ~68, 31 and 58 kDa that corresponds to the expected molecular weights (MW) of P2X7A (solid arrow), 
P2X7E (chevron arrow), and P2X7L (thin arrow), respectively. Panels are from the same image with irrelevant 
lanes cropped out. B) Flow cytometry analyses of HEK 293 cells transiently transfected with P2X7A, E or L 
labelled with APR008 anti-P2X7 pAb (upper panels) or L4 mAb (lower panels). APR008 was positive for P2X7A 
and P2X7L, but not P2X7E. L4, which binds to an epitope located around Arg307, was positive for P2X7A, but 
not P2X7E or P2X7L. C) Western blot analysis of whole-cell lysates from HEK 293 cells following protein 
crosslinking. HEK 293 cells were transiently transfected with EE-tagged P2X7A or L expression constructs and 
crosslinked with BS3. Immunoblots were probed with anti-EE. Trimers, dimers and monomers of P2X7A (A3, 
A2 and A, respectively) and dimers and monomers of P2X7L (L2 and L, respectively) were detected. Panels are 
from the same image with irrelevant lanes cropped out. 
 
Figure 5: P2X7L interacts with P2X7A 
A) Nickel affinity purification of P2X7A-His tagged proteins from HEK 293 cells transfected with P2X7A-
His and P2X7L-EE expression constructs (L+A) or P2X7L-EE alone (L). Whole-cell lysates (left panel) and bead 
eluates (right panel) were separated on an 8% Tris acetate gel and NIR immunoblotting using anti-P2X7 antibody 
was performed. Panels are from the same image with irrelevant lanes cropped out. (B) Duolink PLA performed 
on cell lines stably transfected with P2X7A-EE or P2X7L-EE expression constructs and transiently transfected 
with P2X7A-AcGFP. Transfected cells were identified by GFP fluorescence (top panels, 2 s exposure). Duolink 
PLA interactions are shown in the middle panels (red fluorescence,50 ms exposure) and cell nuclei were identified 
by DAPI staining (bottom panels, blue fluorescence, 16.4 ms exposure). HEK 293 cells transiently transfected 
with P2X7A-AcGFP expression constructs alone were used as negative controls (left panels). 
 
Figure 6: P2X7L forms heteromers with P2X7A 
Nickel affinity purification of P2X7A-His tagged proteins from HEK 293 cells transfected with P2X7A-His 
and P2X7L-EE expression constructs (L+A) or P2X7L-EE alone (L) crosslinked at the cell surface with DTSSP. 
Proteins from whole-cell lysates (A) and bead eluates (B) were separated on 6% Tris-acetate gels under non-
reducing conditions. NIR immunoblotting was performed on duplicate blots with anti-EE to detect P2X7L-EE 
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(Figure 7A and 7B, lanes 1 and 2) or with anti-P2X7 antibody to detect P2X7A-His and P2X7L-EE (Figure 7A 
and 7B, lanes 3 and 4). Panels are from the same image with irrelevant lanes cropped out. A, A2 and A3 indicate 
monomers, dimers and trimers of P2X7A-His, respectively. Bold arrows indicates the position of P2X7L-EE 
trimers; chevron arrow indicates the position of the P2X7L-EE/P2X7A-His heterotrimer. 
 
Figure 7. P2X7L has phagocytic but not channel or pore function  
HEK 293 cells were transfected with P2X7A, P2X7E or P2X7E. A) P2X7 channel function was determined 
by whole-cell patch-clamping. Curves are averaged current traces from P2X7A (n=12), P2X7E (n=9) and P2X7L 
(n=9) in response to ATP 1 mM. The mean and SEM are calculated (**: P<0.001). B) Typical traces of 1mM 
ATP-stimulated Ca2+ influx indicated by Fura-Red intensity over 4 min. Each interval is 2 sec. C) P2X7 pore 
formation as measured by ATP induced ethidium uptake was abolished in HEK 293 cells transfected with P2X7E 
and P2X7L isoform. D) Phagocytosis of YG beads by transfected HEK-293 cells. (**:P<0.001, n=6-7). 
 
Figure 8. P2X7 receptor pore function is altered following co-assembly of P2X7A with P2X7L 
HEK 293 cells were singly-transfected with P2X7A (A), P2X7E (E) or P2X7l (L) or double-transfected with 
P2X7A and P2X7E (A+E) or P2X7L (A+L). Pore function was measured as the rate of ethidium uptake using a 
plate reader-based assay (n = 2-7). Co-transfection with equal amounts of P2X7A and P2X7L significantly 
decreased the rate of ethidium uptake compared to transfection with P2X7A alone. Students t-test *p < 0.0001. 
NT: non-transfected cells. 
 
Table 1: Primer sets for quantitative and qualitative assessment of P2RX7 mRNA isoforms 
Table 2: SNPs predicted to influence exon 7 and 8 skipping 
1Wild-type; 2Heterozygote; 3Homozygote; 4Mean allele frequency; 5Fisher’s exact test was used to determine 
differences between MAF in the two groups. 
Table 3 Haplotype block associated with exon 7 and 8 skipping 
WT: wild-type; HET: heterozygote; HOM: homozygote. *subjects used in exon trapping experiments 
Figure S1: Novel P2RX7 mRNA transcripts 
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Sequences of 5 novel P2RX7 mRNA variants aligned to P2RX7A using the online MAFFT tool 
(https://www.ebi.ac.uk/Tools/msa/mafft/). GenBank accession numbers: P2RX7A, Y09561; P2RX7L, MK465687; 
P2RX7N, MK465688; P2RX7O, MK465689; P2RX7P, MK465690; P2RX7Q, MK465691. 
Figure S2: Amino acid sequence of P2X7L. 
The nucleotide sequence of P2X7L (Figure S1) was translated to protein using an online translation tool 
(https://web.expasy.org/translate/) and aligned with P2X7A(Q99572). Transmembrane regions are highlighted in 
grey. 
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*mRNA isoform groups based on specific exon deletions or insertions: inserted intron 10 (Ins Intron 10), deletion 
exon 4 (Del Exon 4), deletion exon 8 (Del Exon 8), incorporation of a novel exon 3 (Ins N3), deletion exons 7 and 




   
Del Exon7+8 mRNA 
 
  Absent 
                       Present 
SNP  Location n  WT1  HET2  HOM3 MAF4     n  WT  HET  HOM MAF  p-Value5 
rs208307 intron 6 6 6 0 0 0    14 4 8 2 0.43 0.007 
rs503720 intron 7 5 3 2 0 0.20  12 5 5 2 0.38 0.07 
rs7958311 exon 8 6 1 4 1 0.50    17 16 5 0 0.15 0.02 
rs7958316 exon 8 6 6 0 0 0  17 16 1 0 0.03 1.00 
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  WT  HET  HOM 




















rs208306 Intron 6 WT WT WT  HET WT HET  HOM HOM HOM HOM 
rs17526121 Intron 6 HET WT HET  HET WT WT  WT WT WT WT 
rs36144845 Intron 6 WT WT WT  HET HET HET  HOM HOM HOM HOM 
rs208308 Intron 7 WT WT ND  HET HET HET  HOM HOM HOM HOM 
rs208309 Intron 7 WT WT ND  HET HET HET  HOM HOM HOM HOM 
rs373655596 Intron 7 WT WT ND  ND HET HET  HOM HOM HOM HOM 
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